Rothschild Investment LLC Reduces Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rothschild Investment LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,776 shares of the medical equipment provider’s stock after selling 364 shares during the period. Rothschild Investment LLC’s holdings in Zimmer Biomet were worth $610,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. New World Advisors LLC raised its holdings in shares of Zimmer Biomet by 7.3% during the fourth quarter. New World Advisors LLC now owns 3,813 shares of the medical equipment provider’s stock valued at $403,000 after purchasing an additional 260 shares during the last quarter. South Dakota Investment Council grew its position in Zimmer Biomet by 266.6% in the 4th quarter. South Dakota Investment Council now owns 80,886 shares of the medical equipment provider’s stock worth $8,544,000 after purchasing an additional 58,820 shares during the period. World Equity Group Inc. purchased a new stake in Zimmer Biomet during the 4th quarter valued at $256,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Zimmer Biomet by 17.0% during the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 34,447 shares of the medical equipment provider’s stock valued at $3,639,000 after buying an additional 5,000 shares during the period. Finally, Olympiad Research LP purchased a new position in shares of Zimmer Biomet in the 4th quarter worth $228,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $106.00 on Tuesday. The stock has a 50-day moving average price of $105.85 and a 200 day moving average price of $107.44. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The stock has a market capitalization of $21.10 billion, a P/E ratio of 23.82, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.